• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PAROXETINE Drug Record

  • Summary
  • Interactions
  • Claims
  • PAROXETINE chembl:CHEMBL490 Approved

    Alternate Names:

    PEXEVA
    PAXIL
    BRL-29060
    PAROXETINE
    PAXIL [AS HYDROCHLORIDE]
    (−)-(3S,4R)-4-(P-FLUOROPHENYL)-3-((3,4-(METHYLENEDIOXY)PHENOXY)METHYL)PIPERIDINE
    (3S-TRANS)-3-((1,3-BENZODIOXOL-5-YLOXY)METHYL)-4-(4-FLUOROPHENYL)PIPERIDINE
    PAROXETINUM
    (-)-(3S,4R)-4-(P-FLUOROPHENYL)-3-((3,4-(METHYLENEDIOXY)PHENOXY)METHYL)PIPERIDINE
    PAROXETINA
    pubchem.compound:43815
    chembl:CHEMBL490
    drugbank:00715
    chemidplus:61869-08-7
    rxcui:32937

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antidepressant
    Drug Class antidepressive agents, second-generation
    Year of Approval 1992
    (3 More Sources)

    Publications:

    Murata Y et al., 2010, Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome., J Clin Psychopharmacol
    Sugai T et al., 2006, The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine., Pharmacogenomics J
    Bixo et al., 2001, Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment., Psychoneuroendocrinology
    Meyer et al., 2001, The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study., Am J Psychiatry
    Kato M et al., 2009, 5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients., Psychiatry Res
    Wilkie MJ et al., 2009, Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy., Pharmacogenomics J
    Tanaka M et al., 2008, Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea., Int J Neuropsychopharmacol
    Murphy GM Jr et al., 2003, Pharmacogenetics of antidepressant medication intolerance., Am J Psychiatry
    Foster RH et al., 1997, Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder., CNS Drugs
    Newcombe F et al., 1969, Alkaloids of the leaves of Voacanga schweinfurthii Stapf., Planta Med
    Yang Z et al., 2012, Association of APC and REEP5 gene polymorphisms with major depression disorder and treatment response to antidepressants in a Han Chinese population., Gen Hosp Psychiatry
    Kurose K et al., 2012, Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression., Psychiatry Res
    Breitenstein B et al., 2016, Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study., J Psychiatr Res
    Huang X et al., 2013, ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients., Pharmacogenomics
    de Klerk OL et al., 2013, ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder., Pharmacogenomics J
    Perroud N et al., 2011, Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample., Pharmacogenomics
    Uhr M et al., 2008, Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression., Neuron
    Wang XC et al., 2014, Association of 2 neurotrophic factor polymorphisms with efficacy of paroxetine in patients with major depressive disorder in a Chinese population., Ther Drug Monit
    Benedetti F et al., 2009, The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting., Psychopharmacology (Berl)
    Niitsu T et al., 2013, Pharmacogenetics in major depression: a comprehensive meta-analysis., Prog Neuropsychopharmacol Biol Psychiatry
    Zou YF et al., 2010, Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders., Neurosci Lett
    Sarginson JE et al., 2010, FKBP5 polymorphisms and antidepressant response in geriatric depression., Am J Med Genet B Neuropsychiatr Genet
    Kirchheiner J et al., 2008, Genetic variants in FKBP5 affecting response to antidepressant drug treatment., Pharmacogenomics
    Papiol S et al., 2007, Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment., J Affect Disord
    Binder EB et al., 2004, Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment., Nat Genet
    Ishiguro S et al., 2011, Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder., Eur J Clin Pharmacol
    Yevtushenko OO et al., 2010, Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism., J Affect Disord
    Illi A et al., 2009, 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression., Neuroreport
    Kato M et al., 2009, Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder., Am J Med Genet B Neuropsychiatr Genet
    Baune BT et al., 2008, Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression?, Neurosci Lett
    Drago A et al., 2008, 5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies., Int J Neuropsychopharmacol
    Glubb DM et al., 2010, Association of a functional polymorphism in the adrenomedullin gene (ADM) with response to paroxetine., Pharmacogenomics J
    Wang P et al., 2018, Association of DNA methylation in BDNF with escitalopram treatment response in depressed Chinese Han patients., Eur J Clin Pharmacol
    Murphy GM Jr et al., 2013, BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression., Pharmacogenet Genomics
    Musil R et al., 2013, No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression., Eur Arch Psychiatry Clin Neurosci
    Yoshimura R et al., 2011, The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients., Prog Neuropsychopharmacol Biol Psychiatry
    Zou YF et al., 2010, Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients., Neuropsychobiology
    Domschke K et al., 2010, Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response., Int J Neuropsychopharmacol
    Arias B et al., 2013, TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression., Neuropsychobiology
    Dobrinas M et al., 2011, Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility., Clin Pharmacol Ther
    Lin KM et al., 2010, CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine., Pharmacogenomics
    Preuss et al., 2000, Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity., Psychiatry Res
    Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
    Scholze et al., 2000, Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter., J. Pharmacol. Exp. Ther.
    Wihlbäck et al., 2001, Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and serotonin 2A receptor binding., Obstet Gynecol
    Pollock et al., 2000, Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression., Neuropsychopharmacology
    Haughey et al., 2000, The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia., J. Neurochem.
    Davis BA et al., 2016, Mechanism of Paroxetine (Paxil) Inhibition of the Serotonin Transporter., Sci Rep
    Tsuchimine S et al., 2012, DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder: a preliminary study., J Clin Psychopharmacol
  • PAROXETINE   FKBP5

    Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23733030 21449676 20709156 19676097 18597649 17467808 15565110


    Sources:
    PharmGKB

  • PAROXETINE   MDGA2

    Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22445761


    Sources:
    PharmGKB

  • PAROXETINE   REEP5

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22795047


    Sources:
    PharmGKB

  • PAROXETINE   SRP19

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22795047


    Sources:
    PharmGKB

  • PAROXETINE   TPH1

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23733030 23221997 19590397


    Sources:
    PharmGKB

  • PAROXETINE   GDNF

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24577123


    Sources:
    PharmGKB

  • PAROXETINE   ADM

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19636336


    Sources:
    PharmGKB

  • PAROXETINE   HTR3B

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20075642 16534507


    Sources:
    PharmGKB

  • PAROXETINE   SLC6A4

    Interaction Score: 0.5

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name CRx-139
    Novel drug target Established target
    Trial Name paroxetine hydrochloride,Paxil, Seroxat

    PMIDs:
    10980326 9537821 10869387 11530128 11027924 10987842 27032980 23338224


    Sources:
    TdgClinicalTrial TEND

  • PAROXETINE   HTR1A

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23733030 21688171 19800133 19590397 18484082 18387740 18047755


    Sources:
    PharmGKB

  • PAROXETINE   BDNF

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29748862 23733030 23619509 22965830 21338649 20016225 19236730


    Sources:
    PharmGKB

  • PAROXETINE   HTR2A

    Interaction Score: 0.23

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    11403977 11136637 19361869 18253134 17697394 14514498 23338224 5821956


    Sources:
    PharmGKB

  • PAROXETINE   COMT

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18989660


    Sources:
    PharmGKB

  • PAROXETINE   HTR1B

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21449676


    Sources:
    PharmGKB

  • PAROXETINE   DRD3

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22926616


    Sources:
    PharmGKB

  • PAROXETINE   ABCB1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26704739 24192121 22641028 21449676 18215618


    Sources:
    PharmGKB

  • PAROXETINE   CYP3A5

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PAROXETINE   MTOR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAROXETINE   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21593735 21121774


    Sources:
    PharmGKB

  • PAROXETINE   ATXN2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAROXETINE   CYP2D6

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • PAROXETINE   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAROXETINE   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAROXETINE   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TEND: PAROXETINE

    • Version: 01-August-2011

    Alternate Names:
    PAROXETINE Primary Drug Name

    Drug Info:
    Year of Approval 1992
    Drug Class antidepressive agents, second-generation

    Publications:

  • TdgClinicalTrial: PAROXETINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antidepressant
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: paroxetine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Murata Y et al., 2010, Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome., J Clin Psychopharmacol
    Sugai T et al., 2006, The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine., Pharmacogenomics J
    Kurose K et al., 2012, Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression., Psychiatry Res

  • TTD: Paroxetine

    • Version: 2020.06.01

    Alternate Names:
    D06GDY TTD Drug ID

    Drug Info:

    Publications:

  • DTC: PAROXETINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL490 ChEMBL Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL490

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Paroxetine

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21